NEW YORK – A new project is underway in Europe to develop a platform for the direct quantitative measurement of circulating cell-free RNA molecules obtained via liquid biopsy.
The effort, called diaRNAgnosis, also aims to deploy new assays for testicular cancer and prostate cancer based on the platform. The European Commission awarded a consortium of private companies and academic researchers €759,000 ($901,000) recently to carry out their plans. It will commence in January 2021 and run through December 2024.